When Elliott Management knocks, it’s difficult not to answer the door.
The New York investment firm led by legendary activist investor Paul Singer is known for its persistence as it pressures companies to improve their share prices — and its willingness to turn hostile when necessary.
Just ask Ludwig Hantson and the rest of his team at Alexion Pharmaceuticals. Elliott was already dogging Alexion in 2017, just before the biotech relocated to Boston’s Seaport District from New Haven, Conn., two years ago. At that time, though, Elliott wasn’t pushing for a sale — just improvements to operations.
